Integra LifeSciences (IART)
(Delayed Data from NSDQ)
$12.31 USD
-0.83 (-6.32%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $12.30 -0.01 (-0.08%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IART 12.31 -0.83(-6.32%)
Will IART be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IART based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IART
Compared to Estimates, Integra (IART) Q2 Earnings: A Look at Key Metrics
Integra LifeSciences (IART) Beats Q2 Earnings and Revenue Estimates
IART: What are Zacks experts saying now?
Zacks Private Portfolio Services
IART Stock May Rise on First Enrollment in AERA Pediatric Registry
Veracyte (VCYT) Down 13.6% Since Last Earnings Report: Can It Rebound?
Integra (IART) Up 2.3% Since Last Earnings Report: Can It Continue?
Other News for IART
Integra LifeSciences Holdings Corporation (IART) Q2 2025 Earnings Call Transcript
Q2 2025 Integra Lifesciences Holdings Corp Earnings Call Transcript
Integra LifeSciences Reports Q2 2025 Financial Results
Integra LifeSciences (IART) Adjusts FY25 Revenue Guidance
Integra Lifesciences Holdings Corp Reports Q2 Revenue of $415. ...